CancerCheck and Evexia Partner to Enhance Early Cancer Detection Nationwide
Cancer Check Labs has announced a strategic partnership with Evexia Diagnostics to improve early cancer detection across the United States. The collaboration involves CancerCheck, a multi-cancer early detection test that uses a minimally invasive blood test to extract whole circulating tumor cells (CTCs). This test allows a board-certified pathologist to deliver a detailed pathology report. Unlike other tests that rely on biomarkers or DNA, CancerCheck isolates whole CTCs, providing a more accurate diagnosis. The partnership with Evexia will leverage its extensive lab network to make CancerCheck more accessible to clinicians and patients, offering the test through in-office or at-home blood collection. This initiative aims to enhance early cancer detection, potentially identifying cancer as early as Stage 0. 
